Short answer
HAEMONETICS CORP (HAE) filed an 8-K current report with the SEC on August 18, 2026 reporting Item 7.01 (Regulation FD Disclosure). CSL supply agreement expected to increase utilization of Haemonetics products at CSL centers.
HAEMONETICS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- CSL supply agreement expected to increase utilization of Haemonetics products at CSL centers
- Fiscal 2027 financial impact timing remains uncertain, with updates anticipated later
- Revenue opportunity depends on CSL purchase timing, volumes, customer adoption, and Haemonetics’ supply capacity
- Forward-looking statements carry execution and demand risks; no quantified financial impact disclosed
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HAEMONETICS CORP 8-K filings
Get the next HAE 8-K as it lands
Follow HAE for push alerts, or ask the research agent what this filing means.